Publication:
Inducible factors for cancer-associated fibroblasts in liver cancer versus myofibroblasts in inflammatory liver disease

Simple item page
dc.contributor.authorOkabe, Hirohisa
dc.contributor.authorHayashi, Hiromitsu
dc.contributor.authorNakagawa, Shigeki
dc.contributor.authorImai, Katsunori
dc.contributor.authorNitta, Hidetoshi
dc.contributor.authorArima, Kota
dc.contributor.authorHashimoto, Daisuke
dc.contributor.authorChikamoto, Akira
dc.contributor.authorIshiko, Takatoshi
dc.contributor.authorBeppu, Toru
dc.contributor.authorBaba, Hideo
dc.date.accessioned2021-04-12T11:34:36Z
dc.date.available2021-04-12T11:34:36Z
dc.date.issued2016
dc.description.abstractThe importance of cancer-associated fibroblasts (CAFs) in liver cancer, cholangiocarcinoma (CC) and hepatocellular carcinoma (HCC), has been appreciated in the past 5 years. We focused on how they get activated in the tumor microenvironment in this review. Not only hepatic stellate cells (HSCs) but also portal fibroblasts (PFs) have been appreciated to be key players in liver fibrogenesis, and their different roles have just started to be recognized. Since the role of cholangiocyte in biliary fibrogenic disease might have some similarities to that of CC, we focused on the role of cholangiocytes activating stromal fibroblasts, which would presumably be helpful for better understanding the mechanism of tumor-CAFs interaction. In addition, the activation of CAFs should be different from that of CAFs in HCC, which we consider to be potentially similar to MFs in hepatocyte injury-dependent liver fibrogesis. Herein, we describe the activation of CAFs in CC in comparison to MFs seen in other liver diseases such as 1) MFs in liver fibrosis caused by hepatocyte injury such as alcoholic hepatitis, viral hepatitis, and nonalcoholic steatosis, 2) MFs in liver fibrosis caused by cholestatic disease, and 3) CAFs in hepatocellular carcinoma (HCC). This review on the activation of fibroblasts either in liver cancer or in chronic liver disease would contribute to CAF-targeted therapy in liver cancer.es
dc.formatapplication/pdfes
dc.format.extent8es
dc.identifier.citationHistology and Histopathology, vol.31, nÂş2, (2016)
dc.identifier.doi10.14670/HH-11-668
dc.identifier.issn1699-5848
dc.identifier.issn0213-3911
dc.identifier.urihttp://hdl.handle.net/10201/106307
dc.languageenges
dc.publisherUniversidad de Murcia. Departamento de BiologĂ­a Celular e HistologĂ­aes
dc.relationSin financiaciĂłn externa a la Universidades
dc.rightsinfo:eu-repo/semantics/openAccesses
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectCholangiocarcinomaes
dc.subjectHepatocellular carcinomaes
dc.subjectCancer-associated fibroblastes
dc.subjectHepatic stellate celles
dc.subjectPortal fibroblastes
dc.subject.otherCDU::6 - Ciencias aplicadas::61 - Medicina::616 - PatologĂ­a. Medicina clĂ­nica. OncologĂ­aes
dc.titleInducible factors for cancer-associated fibroblasts in liver cancer versus myofibroblasts in inflammatory liver diseasees
dc.typeinfo:eu-repo/semantics/articlees
dspace.entity.typePublicationes
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Okabe-31-141-148-2016.pdf
Size:
608.68 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.39 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Histology and histopathology Vol.31, nÂş2 (2016)